Page last updated: 2024-09-03

gefitinib and azd4547

gefitinib has been researched along with azd4547 in 2 studies

Compound Research Comparison

Studies (gefitinib)	Trials (gefitinib)	Recent Studies (post-2010) (gefitinib)	Studies (azd4547)	Trials (azd4547)	Recent Studies (post-2010) (azd4547)
5,231	566	2,919	117	6	116

Protein Interaction Comparison

Protein	Taxonomy	azd4547 (IC50)
Fibroblast growth factor receptor 1	Homo sapiens (human)	0.006
Fibroblast growth factor receptor 2	Homo sapiens (human)	0.0052
Fibroblast growth factor receptor 4	Homo sapiens (human)	0.3382
Fibroblast growth factor receptor 3	Homo sapiens (human)	0.0068
Vascular endothelial growth factor receptor 2	Homo sapiens (human)	0.0383
Fibroblast growth factor receptor 4	Mus musculus (house mouse)	0.4335

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM	1
He, R; Liu, Y; Luo, H; Luo, J; Pi, G; Quan, J; Su, X; Wang, G; Xiao, H; Ye, Y; Zhang, Q; Zhao, L	1

Other Studies

2 other study(ies) available for gefitinib and azd4547

Article	Year
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck	2016
FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib. Oncology reports, 2018, Volume: 39, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1	2018

Article

Year

FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck

2016

FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.

Oncology reports, 2018, Volume: 39, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1

2018